However, in the sensitivity analysis, the different dose groupings resulted in very similar analyses.
Lack of individual data on actual treatment fields used also meant that we had to use general dose groupings based on typical organ doses from basic treatment fields.
Even though individual organ doses would vary if additional fields were used, we think that it is unlikely that the rank order of organs, and hence our dose groupings, would change significantly.
Summaries of the individual ratios from each of the dose groups from the different experiments for different groupings were also calculated (e.g., for all acute mutagenic chemicals).
In the analyses, using the classification of McFarland and Clarke, (1989), we found that PCBs in a grouping of phenobarbital-type inducers and in another grouping of weak or noninducers of CYP 450 showed the low-dose effects, whereas groupings of PCBs that were mixed-type inducers were not associated with type 2 diabetes.
Although we had twice as many cases (n = 8) exposed to more than 30 mg/day of domperidone, the number was still insufficient to evaluate smaller groupings of doses in this category.
For a descriptive overview, we graphed the incidence of infertility (ever vs. never infertile, as defined above) by radioiodine doses to the thyroid in 20 percentile groupings (i.e., ordered dose categories with 5% of the participants in each category).
Neuroimaging data are increasingly being used to predict potential outcomes or groupings, such as clinical severity, drug dose response, and transitional illness states.
As categorical variables, we created RRT dose categories based on the literature, as well as standard statistical groupings (median, tertiles).
In addition, when we analyzed PCBs using the classification of Wolff et al. (1997), we found that groupings of both estrogenic PCBs and antiestrogenic PCBs showed low-dose effects.
AEs are classified as serious, significant or mild according to the following groupings [ 6]: Serious AE (SAE): any untoward medical occurrences at any dose that results in death, is life-threatening, requires in-patient hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability/incapacity, or is a congenital anomaly/birth defect.
